# US 2025/0050042 A1 · Dry powder formulations filled in an inhaler with improved resistance to humidity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0050042 A1
- Document ID: US20250050042A1
- Status: Published application
- Kind: A1
- Application number: 18/721,472
- Filed: 2022-12-19
- Published: 2025-02-13
- Earliest claimed: 2021-12-21
- Assignees: Chiesi Farmaceutici S.p.A.
- Applicants: Chiesi Farmaceutici S.P.A.
- Inventors: Barbara BASSI; Emanuele COSTA; Daniela COCCONI; Vincenzina SALVATO; Alan TWEEDIE; Marco DI CASTRI; Giuseppe Antonio MULAS; Sara BOTTINI
- Web page: https://patentgrep.com/patent/US20250050042A1

## CPC

- A61M 15/0091: {mechanically breath-triggered}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61M 15/00: Inhalators {(drug delivery in endotracheal tubes A61M16/04)}
- A61M 15/0026: {Hinged caps}
- A61M 2202/062: Desiccants
- A61M 2202/064: Powder
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A drug product includes a multidose dry powder inhalation device. The device has a medicament chamber and a desiccant chamber adjacent to the medicament chamber, and a pharmaceutical composition therein. The pharmaceutical composition includes a pharmaceutically acceptable salt of formoterol, optionally in combination with a pharmaceutically acceptable salt of glycopyrronium and/or beclomethasone dipropionate. The desiccant chamber is filled with molecular sieves.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A drug product comprising a multidose dry powder inhalation device having a pharmaceutical composition within,
the dry powder inhalation device comprising a medicament chamber, and a desiccant chamber adjacent to the medicament chamber and filled with molecular sieves, and
the pharmaceutical composition comprising a pharmaceutically acceptable salt of formoterol as active ingredient, together with an excipient.

### Claim 19 (depends on 18)

The drug product according to claim 18, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable salt of glycopyrronium and/or a pharmaceutically acceptable salt of beclometasone dipropionate as active ingredients.

### Claim 20 (depends on 19)

The drug product according to claim 19, wherein the pharmaceutically acceptable salt of glycopyrronium is a bromide salt of glycopyrronium.

### Claim 21 (depends on 18)

The drug product according to claim 18, wherein the molecular sieves are made of alkaline salts of aluminosilicates, with pores having a diameter from 2 to 50 Angstrom.

### Claim 22 (depends on 21)

The drug product according to claim 21, wherein the pores have a diameter from 3 to 20 Angstrom.

### Claim 23 (depends on 18)

The drug product according to claim 18, wherein the multidose dry powder inhalation device comprises:
a casing having a mouthpiece and delimiting an inhalation channel connected to an opening of the mouthpiece;
a container for storing a powdered medicament, the container being placed in the casing;
a dispensing device placed in the casing and configured to dispense unit doses of the powdered medicament from the container to the inhalation channel for inhalation through the mouthpiece; and
a cover engageable with the casing to close the mouthpiece, the cover comprising a sealing element for humidity resistance,
wherein, when the cover is engaged with the casing and closes the mouthpiece, a main portion of the sealing element is coupled to the opening to tight close said opening.

### Claim 24 (depends on 23)

The drug product according to claim 23, wherein the sealing element comprises a material that is more deformable than a material of the mouthpiece.

### Claim 25 (depends on 23)

The drug product according to claim 23, wherein the sealing element has a hardness between 10 Shore A and 60 Shore A, between 20 Shore A and 50 Shore A, or between 25 Shore A and 35 Shore A.

### Claim 26 (depends on 23)

The drug product according to claim 23, wherein the sealing element comprises or is made of silicone.

### Claim 27 (depends on 23)

The drug product according to claim 23, wherein the sealing element is over-molded to the cover or push-fitted in the cover.

### Claim 28 (depends on 27)

The drug product according to claim 27, wherein the sealing element is glued to the cover.

### Claim 29 (depends on 18)

The drug product according to claim 18, wherein the pharmaceutical composition comprises the active ingredient in micronized form.

### Claim 30 (depends on 18)

The drug product according to claim 18, wherein the excipient comprises
a fraction of fine excipient particles consisting of a physiologically acceptable excipient and magnesium stearate;
a fraction of coarse excipient particles made of a physiologically acceptable excipient and having a particle size comprised between 200 and 400 micron,
wherein the fraction of fine excipient particles is obtained by micronization upon mixing for at least 1 hour.

### Claim 31 (depends on 30)

The drug product according to claim 30, wherein the physiologically acceptable excipient is alpha-lactose monohydrate.

### Claim 32 (depends on 18)

The drug product according to claim 18, wherein the excipient comprises
a fraction of fine excipient particles consisting of alpha-lactose monohydrate and magnesium stearate in amounts comprised between 98 and 99.0% and between 2.0 and 1.0% by weight, respectively; and
a fraction of coarse excipient particles consisting of alpha-lactose monohydrate having a particle size comprised between 210 and 360 micron and a tapped density comprised between 0.65 and 0.75 g/cm3,
wherein a ratio between the fraction of fine excipient particles and the fraction of coarse excipient particles is comprised between 2.5:97.5 and 7.5:92.5 by weight.

### Claim 33 (depends on 18)

The drug product according to claim 18, further comprising a pouch enclosing the dry powder inhalation device.

### Claim 34 (depends on 18)

A process for manufacturing the drug product according to claim 18, said process comprising:
filling the medicament chamber of a multidose dry powder inhalation device with the pharmaceutical composition comprising a pharmaceutically acceptable salt of formoterol, optionally in combination with a pharmaceutically acceptable salt of glycopyrronium and/or beclometasone dipropionate, and
filling the desiccant chamber of said dry powder inhalation device with molecular sieves.
